Curalogic begins Phase III clinical study of grass allergy product  

The Danish biopharmaceutical company has started a Phase III trial of a grass allergy product and plans to file a registration application for the product in Europe in H2 2009
Danish biopharmaceutical company Curalogic has announced in a press release that it has commenced treatment of the first patients in a Phase III clinical study of a grass allergy product.  The study will be conducted in a number of European countries and will involve more than 600 patients before and through the 2008 grass pollen season.
Curalogic expects that the results from the double-blind, placebo-controlled study will be available in Q1 2009, and the company plans to file a registration application for the product in Europe in H2 2009. The active ingredient of the grass allergy product is an extract of pollen from Timothy grass (Phleum pratense).
The market for grass allergy products is sizeable; Curalogic estimates that approximately 51 million people in Europe and 30 million in the US suffer from grass allergy. The company already has a pipeline product for ragweed allergy in Phase III clinical studies.
OMX-listed Curalogic develops products for the treatment of allergy using a patented formulation technology. In addition to the aforementioned Phase III studies, the company has a product for the treatment of cat allergy in Phase II and a product for the treatment of house dust mite allergy at an early stage of development.
Link > Curalogic 

Next step

Explore business cases

Please contact me

How can we help you?

We use cookies to make the website perform optimally. You accept cookies by closing the box or continuing to use the website. Click here to read more about cookies. ×